ArticlePLOS global public health2026
Determinants of left ventricular hypertrophy in a cohort attending a medical clinic: A comparative analysis stratified by sex.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular hypertrophy (LVH) is a significant cardiovascular complication in sub-Saharan Africa. However, sex-specific determinants of LVH in this population remain poorly understood. This study aimed to identify factors associated with LVH in a cohort attending medical clinic, stratified by sex. We conducted a cross-sectional analysis of 333 adults attending an outpatient clinic at Livingstone Teaching Hospital, Zambia. LVH was diagnosed by echocardiography. Data on demographics, clinical history (HIV, TB, hypertension) and metabolic profiles were collected. Univariable and multivariable logistic regression models were used to identify predictors of LVH in the overall cohort and in sex-stratified subgroups. p < 0.05 was considered statistically significant. Data from 333 participants were analysed. LVH was diagnosed in 75 participants (22.5%). In the overall cohort, independent factors associated with LVH were older age (AOR: 1.06 per year, 95% CI: 1.03-1.09, p < 0.0001), female sex (AOR: 2.31, 95% CI: 1.13-4.68, p = 0.020), hypertension (AOR: 2.52, 95% CI: 1.36-4.66, p = 0.003), and heart failure (AOR: 7.50, 95% CI: 1.85-30.3, p = 0.005). Sex-stratified analysis revealed distinct profiles: in males, LVH was significantly associated with older age (AOR: 1.06, 95% CI: 1.00-1.13, p = 0.030), hypertension (AOR: 3.70, 95% CI: 1.03-13.2, p = 0.044), and heart failure (AOR: 18.3, 95% CI: 1.60-209.0, p = 0.019), whereas in females, factors associated with LVH included older age (AOR: 1.06, 95% CI: 1.03-1.09, p < 0.0001), hypertension (AOR: 2.50, 95% CI: 1.21-5.18, p = 0.013), waist circumference (AOR: 1.05 per cm, 95% CI: 1.00-1.10, p = 0.047), and elevated cholesterol-HDL ratio (AOR: 1.53, 95% CI: 1.02-2.30, p = 0.036). LVH in this cohort was associated with age, female sex, hypertension, and heart failure. Factors associated with LVH differed by sex, with metabolic factors playing a more prominent role in women and hemodynamic factors in men. These findings underscore the importance of sex-specific cardiovascular risk assessment and tailored management strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.